Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

PTHS

Pelthos Therapeutics Inc

Nov 26 • 02:25PM ET

29.29

+2.18 8.04 %

Healthcare • Biotechnology • USA • AMEX

Peers: VRTX BMRN SRPT BLUE ALNY IONS NBIX AMGN GILD REGN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-18.46	Insider Own	18.82%	Shs Outstand	3.09M	Perf Week	-2.40%
Market Cap	89.67M	Forward P/E	-	EPS next Y	-	Insider Trans	-1.71%	Shs Float	2.49M	Perf Month	-9.74%
Enterprise Value	78.90M	PEG	-	EPS next Q	-3.04	Inst Own	25.05%	Short Float	0.70%	Perf Quarter	27.40%
Income	-10.07M	P/S	-	EPS this Y	-	Inst Trans	37.60%	Short Ratio	0.96	Perf Half Y	208.32%
Sales	0.00M	P/B	1.55	EPS next Y	-	ROA	-	Short Interest	0.02M	Perf YTD	356.94%
Book/sh	18.85	P/C	6.29	EPS next 5Y	-	ROE	-	52W High	54.29 -46.05%	Perf Year	343.79%
Cash/sh	4.65	P/FCF	-	EPS past 3/5Y	-140.00% -87.88%	ROIC	-16.48%	52W Low	5.51 431.29%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.43% 10.64%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-160.85%	Oper. Margin	-	ATR (14)	3.26	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.01	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	45.66	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.98	EPS Q/Q	-72.86%	SMA20	-9.90%	Beta	4.21	Target Price	63.00
Payout	-	Debt/Eq	0.06	Sales Q/Q	-	SMA50	-5.52%	Rel Volume	0.98	Prev Close	27.11
Employees	4	LT Debt/Eq	0.05	Earnings	Nov 13 BMO	SMA200	41.47%	Avg Volume	18.00K	Price	29.29
IPO	Feb 16, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	-821.74% 68.72%	Trades		Volume	13,581	Change	8.04%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-25-25	Initiated	Roth Capital	Buy	$57
Sep-02-25	Initiated	Oppenheimer	Outperform	$50

Nov-13-25 06:45AM	Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results (GlobeNewswire) -7.27%
Nov-07-25 08:00AM	Pelthos Therapeutics Acquires Xepi (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing (GlobeNewswire) -8.07%
Nov-05-25 08:00AM	Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025 (GlobeNewswire) +6.47%
Oct-09-25 08:00AM	Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum (GlobeNewswire) -7.89%
Sep-08-25 08:30AM	Pelthos Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire) +13.96%
08:00AM	Loading…
Sep-02-25 08:00AM	Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference (GlobeNewswire) -5.03%
Aug-18-25 08:00AM	Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update (GlobeNewswire)
Jul-10-25 08:00AM	Pelthos Therapeutics Launches ZELSUVMI (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum (GlobeNewswire) +60.78%
Jul-02-25 07:00AM	Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement (GlobeNewswire) +22.22%
07:00AM	Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics (GlobeNewswire)

Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. It produces products under its proprietary nitic oxide-based technology platform Nitricil. Its main product is a topical gel for the treatment of molluscum contagiosum. The company was founded on March 19, 2021 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Friedberg Ezra M	Director	Nov 25 '25	Sale	28.03	10,000	280,280	30,000	Nov 26 12:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

PTHS

Pelthos Therapeutics Inc

Upgrade your FINVIZ experience